Research and partners
The score, in the open
NeuroQuest Zen Pro is being built as a biological early signal of physiological strain for overworked professionals and for autistic and ADHD adults. This page is what a partner can audit today.
Validation study planned. Not a diagnostic. Not a medical device.
A 90-day observational study is planned, with IRB oversight, together with Western Kentucky Heart and Lung Research Foundation. Principal investigator: Dr. David Ciochetty. Enrollment target: 92 participants. The study is not finished. It has not produced validation results. NeuroQuest Zen Pro is not a diagnostic, and it is not a medical device.
Formula
Three signals, fixed weights
Score = 0.50·Heart + 0.35·Sleep + 0.15·Strain
Heart is heart-rate variability and heart rate. Sleep is duration and regularity. Strain is physiological load from the wearable. Each term is that day’s signal placed against the person’s own trailing seven-day baseline. The weights are fixed. They are not fit by a machine-learning model, and they do not change from person to person.
Direction of the parts, as designed: recovery-leaning heart rhythm (higher variability, resting heart rate near that person’s baseline) raises the heart term; sleep nearer the person’s own sufficient, regular week raises the sleep term; less strain than the person’s recent week raises the strain term.
The exact scaling used in the study protocol will be published with that protocol. What is public now is the structure: three signals, these weights, seven personal days, no population rank, no trained AI.
Why a baseline
A population average hides the people this is for. A high-load professional and an autistic adult can have very different ordinary weeks. The score asks whether today is heavier than your recent week.
Seven days is short enough to move with life, and long enough that one odd night does not become the whole story.
Study design
What is planned
The study is observational. It is designed to watch how the score moves across 90 ordinary days, alongside wearables people already use. It is not a treatment trial. It is not designed to diagnose autism, ADHD, heart disease, or any other condition.
- Design
- Observational. No assigned treatment.
- Length
- 90 days.
- Enrollment target
- 92 participants.
- Partner
- Western Kentucky Heart and Lung Research Foundation.
- Principal investigator
- Dr. David Ciochetty.
- Oversight
- Planned as an IRB observational study. Approval status should be confirmed with us before anyone describes the study as approved.
- Stage
- Planned. Not a completed validation.
What we will not say
- We will not call the score a diagnosis.
- We will not call the product a medical device.
- We will not say a model was trained to produce the weights. It was not.
- We will not rank people against each other.
- We will not present planned research as finished evidence.
Free tools on this site train and track focus and memory. They do not raise IQ, prevent decline, or treat any condition. See the science note.
Contact
Research partners and investors
Write to hello@neuroquestzen.com. Tell us who you are and what you want to explore. We read these ourselves. The company is NeuroQuest LLC, Bowling Green, Kentucky. Founder: Whitney Ausbrooks.